Page 28 - Read Online

Page 790 Fabbrizi et al. Cancer Drug Resist 2020;3:775-90 I http://dx.doi.org/10.20517/cdr.2020.49

101. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, et al. Specific killing of BRCA2-deficient tumours with inhibitors of
poly(ADP-ribose) polymerase. Nature 2005;434:913-7.
102. Kong A, Good J, Kirkham A, Savage J, Mant R, et al. Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant
treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the WISTERIA trial protocol. BMJ
Open 2020;10:e033009.
103. Seront E, Schmitz S, Papier M, van Maanen A, Henry S, et al. Phase 1 study evaluating the association of the cyclin-dependent kinase
4/6 inhibitor Ribociclib and Cetuximab in recurrent/metastatic p16-negative squamous cell carcinoma of the head and neck. Front Oncol
2019;9:155.
104. Lin CJ, Grandis JR, Carey TE, Gollin SM, Whiteside TL, et al. Head and neck squamous cell carcinoma cell lines: established models
and rationale for selection. Head Neck 2007;29:163-88.
105. Tanaka N, Osman AA, Takahashi Y, Lindemann A, Patel AA, et al. Head and neck cancer organoids established by modification of the
CTOS method can be used to predict in vivo drug sensitivity. Oral Oncol 2018;87:49-57.
106. Driehuis E, Kolders S, Spelier S, Lohmussaar K, Willems SM, et al. Oral mucosal organoids as a potential platform for personalized
cancer therapy. Cancer Discov 2019;9:852-71.